Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFS NASDAQ:MDXG NASDAQ:TNDM NASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$26.46+2.3%$23.10$19.10▼$29.55$1.27B1.78583,602 shs314,440 shsMDXGMiMedx Group$7.14+0.7%$6.90$5.47▼$10.14$1.06B1.74458,070 shs366,086 shsTNDMTandem Diabetes Care$12.58+1.5%$14.07$9.98▼$47.60$850.02M1.452.19 million shs1.61 million shsXAIRBeyond Air$2.21+1.8%$2.92$2.02▼$13.52$11.55M0.28184,814 shs45,110 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions+2.28%+5.63%+25.46%+11.60%+7.21%MDXGMiMedx Group+0.71%+0.56%-1.38%+10.02%+8.51%TNDMTandem Diabetes Care+1.53%+0.56%-12.58%-39.46%-69.41%XAIRBeyond Air+1.84%-0.45%-21.07%-41.81%-74.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$26.46+2.3%$23.10$19.10▼$29.55$1.27B1.78583,602 shs314,440 shsMDXGMiMedx Group$7.14+0.7%$6.90$5.47▼$10.14$1.06B1.74458,070 shs366,086 shsTNDMTandem Diabetes Care$12.58+1.5%$14.07$9.98▼$47.60$850.02M1.452.19 million shs1.61 million shsXAIRBeyond Air$2.21+1.8%$2.92$2.02▼$13.52$11.55M0.28184,814 shs45,110 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions+2.28%+5.63%+25.46%+11.60%+7.21%MDXGMiMedx Group+0.71%+0.56%-1.38%+10.02%+8.51%TNDMTandem Diabetes Care+1.53%+0.56%-12.58%-39.46%-69.41%XAIRBeyond Air+1.84%-0.45%-21.07%-41.81%-74.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.13Buy$31.2918.24% UpsideMDXGMiMedx Group 3.00Buy$12.0068.07% UpsideTNDMTandem Diabetes Care 2.27Hold$22.4778.59% UpsideXAIRBeyond Air 3.50Strong Buy$11.00397.74% UpsideCurrent Analyst Ratings BreakdownLatest XAIR, BLFS, TNDM, and MDXG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$10.35 ➝ $11.008/21/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/13/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/11/2025BLFSBioLife SolutionsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025TNDMTandem Diabetes CareLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$75.00 ➝ $12.008/8/2025BLFSBioLife SolutionsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.00 ➝ $32.008/8/2025TNDMTandem Diabetes CareBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$53.00 ➝ $51.008/7/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$59.00 ➝ $24.008/7/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$30.00 ➝ $14.008/7/2025TNDMTandem Diabetes CareUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$20.00 ➝ $17.008/7/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$20.00 ➝ $13.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$82.25M15.41$0.12 per share215.98$7.52 per share3.52MDXGMiMedx Group$348.88M3.03$0.33 per share21.55$1.31 per share5.45TNDMTandem Diabetes Care$940.20M0.90N/AN/A$4.01 per share3.14XAIRBeyond Air$4.78M2.42N/AN/A$3.32 per share0.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$20.18M-$0.12N/AN/AN/A-5.39%0.16%0.14%11/11/2025 (Estimated)MDXGMiMedx Group$42.42M$0.2134.0022.31N/A8.84%23.03%17.09%10/29/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%11/5/2025 (Estimated)XAIRBeyond Air-$46.62M-$11.93N/AN/AN/A-880.72%-232.61%-115.92%11/10/2025 (Estimated)Latest XAIR, BLFS, TNDM, and MDXG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q1 2026XAIRBeyond Air-$1.50-$1.53-$0.03-$1.53$1.75 million$1.76 million8/7/2025Q2 2025BLFSBioLife Solutions-$0.02-$0.33-$0.31-$0.33$23.71 million$25.42 million8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million7/30/2025Q2 2025MDXGMiMedx Group$0.06$0.10+$0.04$0.06$90.79 million$98.61 million6/17/2025Q4 2025XAIRBeyond Air-$2.80-$1.80+$1.00-$0.09$1.39 million$1.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife SolutionsN/A4.433.45MDXGMiMedx Group0.084.393.90TNDMTandem Diabetes Care2.322.441.88XAIRBeyond Air0.923.242.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%MDXGMiMedx Group79.15%TNDMTandem Diabetes CareN/AXAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%MDXGMiMedx Group1.70%TNDMTandem Diabetes Care1.90%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.90 million46.85 millionOptionableMDXGMiMedx Group870147.96 million145.44 millionOptionableTNDMTandem Diabetes Care2,65067.57 million66.29 millionOptionableXAIRBeyond Air705.23 million4.21 millionOptionableXAIR, BLFS, TNDM, and MDXG HeadlinesRecent News About These CompaniesBeyond Air subsidiary granted orphan designation for malignant glioma treatmentSeptember 3 at 5:42 PM | msn.comBeyond Air, Inc. CEO Steve Lisi to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3 at 8:31 AM | quiverquant.comQBeyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3 at 8:00 AM | globenewswire.comBeyond Air, Inc. Expands Global LungFit® PH Distribution Network to 34 CountriesAugust 20, 2025 | quiverquant.comQBeyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in JapanAugust 20, 2025 | globenewswire.comBeyond Air price target lowered to $5 from $20 at Piper SandlerAugust 14, 2025 | msn.comBeyond Air’s Earnings Call Highlights Growth and ChallengesAugust 13, 2025 | msn.comBeyond Air, Inc. (NASDAQ:XAIR) Q1 2026 Earnings Call TranscriptAugust 13, 2025 | msn.comBeyond Air Reports Strong Revenue Growth in Q1 2026August 13, 2025 | msn.comBeyond Air reports Q1 EPS ($1.53) vs. ($5.32) last yearAugust 12, 2025 | msn.comBeyond Air, Inc. (XAIR) Q1 2026 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comBeyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue EstimatesAugust 12, 2025 | zacks.comBeyond Air Inc (XAIR) Q1 2026 Earnings Report Preview: What To ExpectAugust 12, 2025 | finance.yahoo.comBeyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and WebcastJuly 25, 2025 | globenewswire.comBeyond Air stock surges after securing Premier group purchasing dealJuly 22, 2025 | in.investing.comBeyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.July 22, 2025 | globenewswire.comXAIR | Beyond Air Inc. Annual Cash Flow Statement | MarketWatchJuly 19, 2025 | marketwatch.comD. Boral Capital Initiates Coverage of Beyond Air (XAIR) with Buy RecommendationJuly 18, 2025 | msn.comBeyond Air, Inc. (XAIR) - Yahoo FinanceJuly 12, 2025 | finance.yahoo.comBeyond Air Implements Reverse Stock Split for Nasdaq ComplianceJuly 10, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXAIR, BLFS, TNDM, and MDXG Company DescriptionsBioLife Solutions NASDAQ:BLFS$26.46 +0.59 (+2.28%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$26.46 +0.00 (+0.02%) As of 09/5/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.MiMedx Group NASDAQ:MDXG$7.14 +0.05 (+0.71%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$7.14 0.00 (0.00%) As of 09/5/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Tandem Diabetes Care NASDAQ:TNDM$12.58 +0.19 (+1.53%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$12.72 +0.14 (+1.11%) As of 09/5/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.Beyond Air NASDAQ:XAIR$2.21 +0.04 (+1.84%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.25 +0.04 (+1.76%) As of 09/5/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
